## **Core Concept**
The DOTS (Directly Observed Treatment, Short-course) strategy, now part of the Revised National Tuberculosis Control Programme (RNTCP), employs a standardized treatment regimen for tuberculosis (TB) that includes an intensive phase followed by a continuation phase. The management of TB patients under this strategy is categorized based on the severity and type of TB.

## **Why the Correct Answer is Right**
In the DOTS strategy, Category I patients typically include new smear-positive pulmonary TB patients, new smear-negative pulmonary TB patients with extensive lung parenchymal involvement, and patients with severe forms of extrapulmonary TB. The intensive phase for Category I patients usually consists of four drugs (rifampicin, isoniazid, pyrazinamide, and ethambutol) for 2 months. If a patient remains sputum-positive after the intensive phase, it indicates a slow response or potential drug resistance. According to the RNTCP guidelines, such patients are classified as having a "slow response" and are managed by extending the intensive phase for an additional month, which is essentially adding one more month of the intensive phase drugs.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option does not align with the standard protocol for managing patients who remain sputum-positive after the initial 2 months of intensive phase treatment under the DOTS strategy.
- **Option B:** Changing to a regimen typically reserved for retreatment or drug-resistant cases without confirming drug resistance through appropriate testing would not be the immediate next step based solely on being sputum-positive after 2 months.
- **Option C:** While drug susceptibility testing (DST) is crucial for guiding treatment in cases of suspected drug resistance, immediate action based on a positive sputum smear after 2 months involves adjusting the current regimen rather than waiting for DST results.
- **Option D:** This option might seem plausible but does not accurately reflect the immediate recommended action under the DOTS strategy for a sputum-positive patient after 2 months of intensive treatment.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that if a Category I patient remains sputum-positive after 2 months of intensive phase treatment, the recommended approach under the DOTS strategy is to extend the intensive phase for an additional month before reassessing.

## **Correct Answer:** . **extend the intensive phase for one more month**

✓ Correct Answer: B. Continue the intensive phase of treatment with 4 drugs for 1 more month only, regardless of sputum positivity after that